Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network

INTRODUCTION: Carfilzomib, a potent, irreversible, selective proteasome inhibitor has demonstrated consistent results in relapsed/refractory multiple myeloma (RRMM) combined with lenalidomide and dexamethasone (KRd). No prospective studies are yet available that analyzed the efficacy of the KRd comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Antonioli, Elisabetta, Pilerci, Sofia, Attucci, Irene, Buda, Gabriele, Gozzetti, Alessandro, Candi, Veronica, Simonetti, Federico, Giudice, Maria Livia Del, Ciofini, Sara, Staderini, Michela, Grammatico, Sara, Buzzichelli, Alessandra, Messeri, Maria, Bocchia, Monica, Galimberti, Sara, Vannucchi, Alessandro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166989/
https://www.ncbi.nlm.nih.gov/pubmed/37182182
http://dx.doi.org/10.3389/fonc.2023.1162990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166989/
https://www.ncbi.nlm.nih.gov/pubmed/37182182
http://dx.doi.org/10.3389/fonc.2023.1162990

Ejemplares similares